PHARMACEUTICALS
FOCUSED ON AI
& NOVEL DRUG
ALTERNATIVES
LEADERS
IN DRUG
DESIGN
OUR PARTNERS
At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems, including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.
Significant Achievements to Date
2020
Raised $55M for BIOMEA FUSION spin-off company focused on MLL-Menin.
Partnership with Laxai to Develop Mpro Inhibitors for the Treatment of COVID-19
2018
2019
Partnership with DAEWOONG Pharmaceutical to develop oncology therapeutics.
Partnership with Insilico Medicine to develop a novel therapeutics for Duchenne Muscular Dystrophy.
2018
Raised a Total of $5M in Financing with $3.7M Directly in A2A
Awarded Johnson & Johnson Innovation and Janssen Research & Development's Artificial Intelligence for Drug Discovery Quickfire Challenge.
2017
Revenue generating pilot projects with Novartis and Proctor & Gamble to sign new drug candidates.
Biomea JV Formation for Taking the MLL-Menin program into IND with former Pharmacyclics management
2016
Seed funding through SOSV and incubation at IndieBio.
TECHNOLOGY
